The Patent Finder

Fate Therapeutics, Inc.

46 patents currently held · Updated Nov 16, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Dec 2031
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jun 26, 2027
    The maintenance fee for Composition and Methods for Inducing Myeloid Suppressive Cells and Use Thereof (US 11,851,677) comes due Jun 26, 2027. Unpaid by Dec 27, 2027, it lapses early.
  • 1 fee due Sep 19, 2027
    The maintenance fee for Compositions and methods for immune cell modulation in adoptive immunotherapies (US 11,932,870) comes due Sep 19, 2027. Unpaid by Mar 20, 2028, it lapses early.
  • 1 fee due Oct 21, 2027
    The maintenance fee for Methods and Compositions for Inducing Hematopoietic Cell Differentiation (US 10,626,372) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 10,844,356Cell Culture Platform for Single Cell Sorting and Enhanced Reprogramming of Ipscs
In force
 · High confidence
In forceHigh confidence
US 9,403,885Novel WNT Compositions and Therapeutic Uses of Such Compositions
In force
 · High confidence
In forceHigh confidence
US 9,873,722WNT Compositions and Therapeutic Uses of Such Compositions
In force
 · High confidence
In forceHigh confidence
US 9,452,186Enhanced stem cell composition
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,980,838Methods of treating ischemia
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,172,888Enhanced Stem Cell Composition
In force
 · Low confidence
In forceLow confidence
US 9,732,319Cell Culture Platform for Single Cell Sorting and Enhanced Reprogramming of Ipscs
In force
 · High confidence
In forceHigh confidence
US 11,052,118Enhanced stem cell composition
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,415,989Cell Culture Platform for Single Cell Sorting and Enhanced Reprogramming of Ipscs
In force
 · High confidence
In forceHigh confidence
US 10,023,879Minimal volume reprogramming of mononuclear cells
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 46 patents shown.
Pro members see all 46.
Pro members: see all 46 patents
Also on record, not counted in the 46: 1 patent in force now held by others · 4 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

25 pending · 7 abandoned · 15 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited